Literature DB >> 2833917

Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.

H K Lyerly1, D L Reed, T J Matthews, A J Langlois, P A Ahearne, S R Petteway, K J Weinhold.   

Abstract

Cytophilic antibodies which mediate antibody dependent cellular cytotoxicity (ADCC) against envelope antigens of human immunodeficiency virus (HIV) can be found in seropositive individuals. In these experiments, sera from a wide spectrum of HIV infected patients ranging from asymptomatic to overt acquired immunodeficiency syndrome (AIDS) were shown to contain high titers of antibodies that mediate ADCC. Not only did patient antibodies bind to surface expressed viral antigens and mediate ADCC against cells chronically infected with human T-lymphotropic virus type IIIB (HTLV-IIIB), but also against cells infected with the divergent HTLV-IIIRF2 and HTLV-IIIMN viral isolates. Similar results were obtained with target cells bearing purified GP 120 from HTLV-IIIB and HTLV-IIIRF2, indicating that a major portion of the activity was mediated by anti-GP 120 antibodies. Consistent with this was the ability to absorb most of the group-specific ADCC activity from the serum of an HIV infected individual using affinity columns bearing purified HTLV-IIIB GP 120. The finding that human antibodies reactive against the HIV envelope glycoprotein mediate ADCC against cells chronically infected with divergent strains of HIV will have important implications in designing rational approaches to passive and active immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2833917     DOI: 10.1089/aid.1987.3.409

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  51 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

3.  A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.

Authors:  P A Broliden; K Ljunggren; J Hinkula; E Norrby; L Akerblom; B Wahren
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

Review 4.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

5.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.

Authors:  P L Earl; S Koenig; B Moss
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

7.  Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.

Authors:  Jiehua Zhou; Sangeetha Satheesan; Haitang Li; Marc S Weinberg; Kevin V Morris; John C Burnett; John J Rossi
Journal:  Chem Biol       Date:  2015-03-05

8.  Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection.

Authors:  S J Lin; R L Roberts; B J Ank; Q H Nguyen; E K Thomas; E R Stiehm
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

9.  Quantitation of antigen-specific immune responses in human immunodeficiency virus (HIV)-infected individuals by limiting dilution analysis.

Authors:  S Sabbaj; M F Para; R J Fass; P W Adams; C G Orosz; C C Whitacre
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

10.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.